Pipeline
Pipeline & clinical development
VET3-TGI is being evaluated by intratumoral and intravenous delivery, alone and with atezolizumab.
Pipeline
Development programs
Indication
Preclinical
Phase 1
Phase 1b
Phase 2
VET3-TGI
CPI-refractory Merkel cell carcinoma
Intratumoral · ± atezolizumab
CPI-refractory advanced melanoma
Intratumoral · ± atezolizumab
CPI-resistant and refractory solid tumors
Intratumoral · e.g. MSS-CRC, NSCLC, bladder
Advanced solid tumors
Intravenous · dose escalation ongoing
Preclinical candidate
VET6-PDI
Advanced or metastatic solid tumors
Partnered program
ASP1012 (formerly VET2-L2)
Systemic oncolytic immunotherapy · advanced or metastatic solid tumors
Phase 1 · Partnered with Astellas Pharma
Atezolizumab supplied by Roche. ASP1012 (VET2-L2) is licensed to Astellas Pharma. The program continues to advance under a revised development arrangement pursuant to an amendment to the original licensing agreement. Programs are subject to change based on emerging data and regulatory feedback.
Clinical trial
STEALTH-001 is now enrolling
A first-in-human Phase 1/1b study built to evaluate route, dose, monotherapy and combination potential, with intratumoral expansion in cutaneous tumors and intravenous dose escalation ongoing. ClinicalTrials.gov: NCT06444815.